MalarVx, Inc.
MalarVx, Inc. is a Seattle-based biopharmaceutical company dedicated to developing effective malaria vaccines. Founded in 2012, the company aims to eradicate malaria through innovative technologies, including RNA-based vaccines and in vitro culture systems for the malaria parasite. They focus on creating safe, effective, and long-lasting vaccines to combat malaria globally, addressing the significant health burden caused by _Plasmodium_ parasites, especially in endemic regions like sub-Saharan Africa.
Industries
Nr. of Employees
small (1-50)
MalarVx, Inc.
1551 Eastlake Avenue East Suite 100 Seattle, WA 98102-3788
Products
Replicon RNA-based CSP malaria vaccine candidate
A clinical-stage malaria vaccine candidate using self-amplifying replicon RNA encoding circumsporozoite protein antigens formulated with lipid nanoparticle-style delivery for induction of immune responses against Plasmodium falciparum.
In vitro-cultured sporozoite whole-organism vaccine project
Research and development project focused on producing attenuated or whole-organism malaria vaccine materials via in vitro culture of mosquito-stage parasites to reduce dependence on mosquito-derived sporozoites.
Replicon RNA-based CSP malaria vaccine candidate
A clinical-stage malaria vaccine candidate using self-amplifying replicon RNA encoding circumsporozoite protein antigens formulated with lipid nanoparticle-style delivery for induction of immune responses against Plasmodium falciparum.
In vitro-cultured sporozoite whole-organism vaccine project
Research and development project focused on producing attenuated or whole-organism malaria vaccine materials via in vitro culture of mosquito-stage parasites to reduce dependence on mosquito-derived sporozoites.
Services
Partnered R&D collaborations with academic labs, research institutes, and industry partners for vaccine formulation, immunology analysis, and parasite culture.
Partnered R&D collaborations with academic labs, research institutes, and industry partners for vaccine formulation, immunology analysis, and parasite culture.
Expertise Areas
- Clinical-stage vaccine development
- Malaria parasite biology and in vitro culture
- Vaccine formulation and nucleic acid delivery
- Whole-organism vaccine production
Key Technologies
- Self-amplifying replicon RNA (replicon RNA) platforms
- Lipid nanoparticle-style vaccine delivery
- In vitro sporozoite and mosquito-stage culture systems
- Whole-organism vaccine production methods
News & Updates
In November 2024, at the ASTMH annual conference in New Orleans, Louisiana, Dr. Marion Avril, PI and Program Director at MalarVx, presented a poster on their cultured in vitro sporozoites research project. Zach MacMillen also presented a poster on their cGMP manufacturing of repRNA-based CSP malaria vaccine project.
MalarVx captured live footage of Plasmodium falciparum microgametes actively seeking macrogametes from in vitro cultures, marking a significant advancement in understanding malaria transmission.
MalarVx announced a license to HDT Bio’s proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION™) technologies for use in malaria vaccines, supporting the development and commercialization of malaria vaccines.
In November 2024, at the ASTMH annual conference in New Orleans, Louisiana, Dr. Marion Avril, PI and Program Director at MalarVx, presented a poster on their cultured in vitro sporozoites research project. Zach MacMillen also presented a poster on their cGMP manufacturing of repRNA-based CSP malaria vaccine project.
MalarVx captured live footage of Plasmodium falciparum microgametes actively seeking macrogametes from in vitro cultures, marking a significant advancement in understanding malaria transmission.
MalarVx announced a license to HDT Bio’s proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LION™) technologies for use in malaria vaccines, supporting the development and commercialization of malaria vaccines.